Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-CD19 CAR-T (The First Affiliated Hospital of Nanchang University)
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Nanchang University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-CD19 CAR-T (The First Affiliated Hospital of Nanchang University) is an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy. It is being developed by The First Affiliated Hospital of Nanchang University for the treatment of relapsed or refractory B-cell malignancies, including acute lymphoblastic leukemia (ALL) and various lymphomas. The therapy works by engineering a patient's own T cells to express a CAR that specifically targets the CD19 antigen, a protein widely expressed on the surface of B-lineage cells. Upon infusion, these modified T cells recognize and eliminate CD19-positive cancerous cells through direct cytotoxic activity. The therapy is currently being evaluated in Phase 1/2 clinical trials to determine its safety and efficacy profile in adult patients.
- Other names
- Anti-CD19 CAR-TAnti-CD-19 CAR-TAnti-CD 19 CAR-TAnti-CD19 CAR-T cellsAnti-CD-19 CAR-T cellsAnti-CD 19 CAR-T cells
02
Targets
Beyond the preview
Go deeper on Anti-CD19 CAR-T (The First Affiliated Hospital of Nanchang University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-CD19 CAR-T (The First Affiliated Hospital of Nanchang University).